Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation
- PMID: 15494429
- DOI: 10.1182/blood-2004-08-3213
Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation
Abstract
Allogeneic bone marrow transplantation (BMT) is a potentially curative treatment for both inherited and acquired diseases of the hematopoietic compartment; however, its wider use is limited by the frequent and severe outcome of graft-versus-host disease (GVHD). Unfortunately, efforts to reduce GVHD by removing donor T cells have resulted in poor engraftment and elevated disease recurrence. Alternative cell populations capable of supporting allogeneic hematopoietic stem/progenitor cell engraftment without inducing GVHD could increase numbers of potential recipients while broadening the pool of acceptable donors. Although unfractionated CD4(+) T cells have not been shown to be an efficient facilitating population, CD4(+)CD25(+) regulatory cells (T-reg's) were examined for their capacity to support allogeneic hematopoietic engraftment. In a murine fully major histocompatibility complex (MHC)-mismatched BMT model, cotransplantation of donor B6 T-reg's into sublethally conditioned BALB/c recipients supported significantly greater lineage-committed and multipotential donor progenitors in recipient spleens 1 week after transplantation and significantly increased long-term multilineage donor chimerism. Donor engraftment occurred without GVHD-related weight loss or lethality and was associated with tolerance to donor and host antigens by in vitro and in vivo analyses. Donor CD4(+)CD25(+) T cells may therefore represent a potential alternative to unfractionated T cells for promotion of allogeneic engraftment in clinical hematopoietic cell transplantation.
Similar articles
-
The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.Biol Blood Marrow Transplant. 2002;8(11):588-96. doi: 10.1053/bbmt.2002.v8.abbmt080588. Biol Blood Marrow Transplant. 2002. PMID: 12463477
-
A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.Blood. 1997 Apr 15;89(8):2880-90. Blood. 1997. PMID: 9108408
-
Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.Blood. 1995 Jun 1;85(11):3302-12. Blood. 1995. PMID: 7756664
-
Chimerism and tolerance: from freemartin cattle and neonatal mice to humans.Hum Immunol. 1997 Feb;52(2):155-61. doi: 10.1016/S0198-8859(96)00290-X. Hum Immunol. 1997. PMID: 9077564 Review.
-
Hematopoietic cell transplantation for the induction of allo- and xenotolerance.Clin Transplant. 1996 Aug;10(4):357-63. Clin Transplant. 1996. PMID: 8884109 Review.
Cited by
-
The Effects of Immunosuppressive Factors on Primary Dendritic Cells from C57BL/6 and CBA Mice.J Immunol Res. 2019 Apr 18;2019:7029726. doi: 10.1155/2019/7029726. eCollection 2019. J Immunol Res. 2019. PMID: 31143783 Free PMC article.
-
Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.Biol Blood Marrow Transplant. 2018 Sep;24(9):1788-1794. doi: 10.1016/j.bbmt.2018.04.026. Epub 2018 May 8. Biol Blood Marrow Transplant. 2018. PMID: 29751114 Free PMC article.
-
Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD.Blood Adv. 2024 Mar 12;8(5):1105-1115. doi: 10.1182/bloodadvances.2023011625. Blood Adv. 2024. PMID: 38091578 Free PMC article. Clinical Trial.
-
Regulatory T Cells: Serious Contenders in the Promise for Immunological Tolerance in Transplantation.Front Immunol. 2015 Aug 31;6:438. doi: 10.3389/fimmu.2015.00438. eCollection 2015. Front Immunol. 2015. PMID: 26379673 Free PMC article. Review.
-
Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.Transplant Cell Ther. 2023 May;29(5):341.e1-341.e9. doi: 10.1016/j.jtct.2023.02.015. Epub 2023 Feb 18. Transplant Cell Ther. 2023. PMID: 36804930 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials